STOCK TITAN

Haemonetics Announces CE Mark Certification for the VASCADE MVP® XL Venous Vascular Closure System

(Neutral)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Haemonetics (NYSE: HAE) received CE Mark certification for its VASCADE MVP XL venous vascular closure system under the European Medical Device Regulation.

The certification covers closure of femoral vein access sites after catheter-based procedures using sheaths with a 10–12F inner diameter and a maximum 15F outer diameter. It covers single or multiple access sites in one or both limbs and enables Haemonetics to offer the device in the EU and other markets that recognize CE marking. The first commercial European procedures took place in October in Germany, Italy and the UK.

Loading...
Loading translation...

Positive

  • Minor pointCE Mark certification for VASCADE MVP XL enables sales in the EU and other markets that recognize CE marking.
  • Minor pointFirst commercial European procedures with VASCADE MVP XL were completed in October in Germany, Italy and the UK.

Negative

  • None.

Key Figures

Collagen increase: 58% more Disc size increase: 9% larger Procedural sheath inner diameter: 10–12F +1 more
Collagen increase
58% more
VASCADE MVP XL vs. VASCADE MVP
Disc size increase
9% larger
VASCADE MVP XL vs. VASCADE MVP
Procedural sheath inner diameter
10–12F
VASCADE MVP XL indicated procedures
Maximum sheath outer diameter
15F
VASCADE MVP XL indicated procedures

Key Terms

eu-mdr, hemostasis, percutaneous, pulsed field ablation (pfa)
4 terms
eu-mdr regulatory
"CE marked under the EU-MDR (European Medical Device Regulation)"
EU-MDR is the European Union Medical Device Regulation that sets uniform legal requirements for placing medical devices on the EU market. As an EU regulation (directly applicable in member states), it defines device classification, clinical evaluation and investigation standards, conformity-assessment procedures carried out by notified bodies, post-market surveillance and vigilance obligations, labeling and Unique Device Identification (UDI) rules, and the requirements for CE marking and market access. It replaces earlier directive-based rules and increases regulatory oversight by tightening safety, documentation, and traceability requirements for manufacturers and authorized representatives operating in the EU.
hemostasis medical
"time to hemostasis and time to discharge eligibility"
Hemostasis is the body’s process for stopping bleeding, using a coordinated set of responses that form clots and seal damaged vessels—think of it as the body's natural emergency patch and repair crew. It matters to investors because drugs, medical devices, and diagnostics that influence hemostasis can affect patient outcomes, regulatory approval paths, and market demand for treatments of bleeding disorders or clot-related conditions, so advances or safety issues can materially impact company value.
percutaneous medical
"for the percutaneous closure of femoral venous access sites"
Percutaneous describes medical procedures or delivery methods that reach internal organs or tissues by passing through the skin — for example with needles, catheters or small tubes — instead of opening the body with large incisions. For investors it matters because percutaneous approaches are generally less invasive, often mean lower hospital time, quicker recovery and smaller device footprints, which can broaden market adoption and affect regulatory and reimbursement outlooks.
pulsed field ablation (pfa) medical
"cryoablation or Pulsed Field Ablation (PFA) procedures"
Pulsed field ablation (PFA) is a medical procedure that uses short, high-voltage electric pulses to selectively disable small areas of heart tissue that cause abnormal rhythms, effectively creating tiny barriers that stop errant electrical signals. For investors, PFA matters because it represents a new approach to treating heart rhythm disorders with potential advantages in speed, precision and safety over older methods, which can affect device sales, regulatory approvals and adoption by hospitals and clinicians.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google

First Commercial European Procedures Completed in Germany, Italy and the UK

BOSTON, Nov. 18, 2026 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE), a global medical technology company focused on delivering innovative solutions designed to improve patient outcomes, today announced CE Mark certification for the VASCADE MVP® XL venous vascular closure system, enabling Haemonetics to broaden its global presence and bring new vascular closure benefits to physicians in the European Union (EU) and other geographies that recognize CE marking. The first European procedures with the VASCADE MVP XL system were performed in October by Prof. Christian H. Heeger at Asklepios Clinic Altona in Hamburg, Germany, Prof. Claudio Tondo at Centro Cardiologico Monzino, IRCCS, in Milan, Italy, and Dr. Riyaz A. Kaba at Cromwell Hospital in London, UK.

VASCADE MVP XL is CE marked under the EU-MDR (European Medical Device Regulation) for the percutaneous closure of femoral venous access sites while reducing time to ambulation, total post-procedure time, time to hemostasis and time to discharge eligibility compared to conventional closure methods, and enabling same-day discharge in patients who have undergone catheter-based procedures using 10–12F inner diameter (15F maximum outer diameter) procedural sheaths, with single or multiple access sites in one or both limbs. Using 58% more collagen and a 9% larger disc than the VASCADE MVP® system, the VASCADE MVP XL system provides a robust closure solution for procedures requiring 10-12F sheaths (up to 15F outer diameter) such as cryoablation or Pulsed Field Ablation (PFA) procedures and Left Atrial Appendage Closure (LAAC).

"VASCADE MVP XL has driven the growth of our Interventional Technologies business in the United States, delivering physicians key benefits in larger-bore venous closure supported by clinical evidence. With CE Mark certification and the first cases completed in Europe, we look forward to significantly expanding our impact and commercial momentum in electrophysiology and interventional cardiology as we help raise standards of care for a larger population of patients in new markets around the world," said Ken Crowley, Vice President and General Manager, Interventional Technologies at Haemonetics.

"The VASCADE MVP system has become an important part of our approach to post-procedure care, helping us shorten time to ambulation and facilitate earlier discharge for appropriate patients," said Prof. Dr. Christian H. Heeger, Director Department of Rhythmology at Asklepios Clinic Altona in Hamburg, Germany. "With the VASCADE MVP XL system, we can now apply the same closure technology more confidently in procedures requiring larger venous access within the approved indication."

In addition to the VASCADE MVP XL system, Haemonetics' vascular closure portfolio includes the VASCADE® vascular closure system, designed for "small-bore" femoral arterial and venous closure with standard 5-6/7F procedural sheaths, and the VASCADE MVP system, designed for "mid-bore" multi-access femoral venous closure with 6-12F ID procedural sheaths. Both closure devices are CE marked under the EU-MDR for use in patients who have undergone catheter-based procedures and include proprietary collapsible disc technology and a resorbable collagen plug to achieve hemostasis.

ABOUT HAEMONETICS

Haemonetics is a global medical technology company dedicated to improving the quality, effectiveness, and efficiency of health care. Our Apheresis business features proprietary technologies designed to enhance safety, yield, donor satisfaction and operational efficiency for plasma and blood collectors around the world. Our MedSurg business offers Blood Management Technologies to help inform treatment decisions and optimize the management of blood products, and Interventional Technologies, including advanced vascular closure systems and sensor-guided technologies, designed to drive procedural effectiveness and elevate the patient experience. To learn more about Haemonetics, visit www.haemonetics.com.

Cautionary Statement Regarding Forward-Looking Information

Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements. Forward-looking statements in this press release may include, without limitation, statements regarding plans and objectives of management for the operation of Haemonetics, including statements regarding potential benefits associated with the VASCADE MVP XL venous vascular closure system and Haemonetics' plans or objectives related to the commercialization of such product. Such forward-looking statements are not meant to predict or guarantee actual results, performance, events or circumstances and may not be realized because they are based upon Haemonetics' current projections, plans, objectives, beliefs, expectations, estimates and assumptions and are subject to a number of risks and uncertainties and other influences. Actual results and the timing of certain events and circumstances may differ materially from those described by the forward-looking statements as a result of these risks and uncertainties. Factors that may influence or contribute to the inaccuracy of the forward-looking statements or cause actual results to differ materially from expected or desired results may include, without limitation, product quality; market acceptance; the effect of economic and political conditions; and the impact of competitive products and pricing. These and other factors are identified and described in more detail in Haemonetics' periodic reports and other filings with the U.S. Securities and Exchange Commission. Haemonetics does not undertake to update these forward-looking statements.

Investor Contacts:


Olga Guyette, Vice President-Investor Relations & Treasury

David Trenk, Sr. Manager-Investor Relations

(781) 356-9763

(203) 733-4987

olga.guyette@haemonetics.com

david.trenk@haemonetics.com




Media Contact:


Josh Gitelson, Sr. Director-Global Communications

(781) 356-9776


josh.gitelson@haemonetics.com

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/haemonetics-announces-ce-mark-certification-for-the-vascade-mvp-xl-venous-vascular-closure-system-302942972.html

SOURCE Haemonetics Corporation

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What use does Haemonetics’ VASCADE MVP XL CE Mark certification cover?

The certification covers closure of femoral vein access sites after catheter-based procedures using sheaths with a 10–12F inner diameter and a maximum 15F outer diameter. It applies to single or multiple access sites in one or both limbs.

Where did Haemonetics’ first commercial European procedures with VASCADE MVP XL take place?

The first procedures took place in October at Asklepios Clinic Altona in Hamburg, Germany; Centro Cardiologico Monzino, IRCCS in Milan, Italy; and Cromwell Hospital in London, UK.

Keep reading